Real‐world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load

Data on tenofovir disoproxil fumarate (TDF) therapy for preventing vertical transmission of hepatitis B virus (HBV) in the real‐world setting are limited.

[1]  Noele P. Nelson,et al.  Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B , 2018, The New England journal of medicine.

[2]  Ming Liu,et al.  The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B , 2018, The American Journal of Gastroenterology.

[3]  D. Lu,et al.  An expert consensus for the management of chronic hepatitis B in Asian Americans , 2018, Alimentary pharmacology & therapeutics.

[4]  [A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015]. , 2018, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[5]  James S. Park,et al.  Viral factors for HBV mother-to-child transmission , 2017, Hepatology International.

[6]  C. Pan,et al.  Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B , 2017, Journal of viral hepatitis.

[7]  Fengqiong Yang.  Prevention of Peripartum Hepatitis B Transmission. , 2016, New England Journal of Medicine.

[8]  Shuqin Zhang,et al.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.

[9]  Mei-Hwei Chang,et al.  Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus , 2015, Hepatology.

[10]  L. Lou,et al.  Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. , 2015, World journal of gastroenterology.

[11]  S. Locarnini,et al.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. , 2014, Journal of hepatology.

[12]  C. Pan,et al.  Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. , 2014, Journal of hepatology.

[13]  Hua Zhang,et al.  Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. , 2014, Hepatology.

[14]  Z. Duan,et al.  Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  H. Hsu,et al.  Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. , 2013, Journal of hepatology.

[16]  C. Pan,et al.  Antiviral Therapy for Chronic Hepatitis B in Pregnancy , 2013, Seminars in Liver Disease.

[17]  Xiaofeng Liang,et al.  An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  K. Reddy,et al.  Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series , 2012, Digestive Diseases and Sciences.

[19]  Hong Zhang,et al.  Virologic factors associated with failure to passive–active immunoprophylaxis in infants born to HBsAg‐positive mothers , 2012, Journal of viral hepatitis.

[20]  Wei Zhao,et al.  A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. , 2011, Journal of hepatology.

[21]  Wen Chen,et al.  Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. , 2011, Fertility and sterility.

[22]  P. Perumalswami,et al.  Pregnancy-related liver diseases. , 2011, Clinics in liver disease.

[23]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[24]  Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data--United States. , 2011, MMWR. Morbidity and mortality weekly report.

[25]  Huy Trinh,et al.  Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. , 2011, Gastroenterology.

[26]  H. Zhuang,et al.  [Prevention of hepatitis B virus vertical transmission: current situation and challenges.]. , 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[27]  Hung‐Chih Yang,et al.  Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study , 2009, Journal of viral hepatitis.

[28]  C. Pan,et al.  Revisiting the Natural History of Chronic Hepatitis B in Asian Americans , 2009 .

[29]  J. X. Zhang,et al.  Natural History and Clinical Consequences of Hepatitis B Virus Infection , 2005, International journal of medical sciences.

[30]  W. Fetter,et al.  Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. , 1997, Vaccine.

[31]  L. Hwang,et al.  Postnatal infectivity of hepatitis B surface antigen-carrier mothers. , 1983, The Journal of infectious diseases.